`
`By: Daniel R. Evans
`Registration No. 55,868
`MERCHANT & GOULD P.C.
`191 Peachtree Street, NE
`Suite 3800
`Atlanta, GA 30303
`Main Telephone: 404.954.5100
`Main Facsimile: 612.332.9081
`
`
`
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE BEFORE THE PATENT
`
`TRIAL AND APPEAL BOARD
`
`BRECKENRIDGEG PHARMACEUTICAL, INC.
`
`Petitioner, v.
`
`NOVARTIS PHARMACEUTICALS CORPORATION
`
`Patent Owner.
`
`Case: IPR2017-01592
`U.S. Patent No. 8,410,131
`
`
`
`
`
`
`
`
`
`PETITIONER’S REVISED MANDATORY NOTICES
`
`
`
`
`Petitioner, Breckenridge Pharmaceutical, Inc., hereby submits its Revised
`
`Case No. IPR2017-01592
`U.S. Patent No. 8,410,131
`
`
`
`
`Mandatory Notices pursuant to 37 C.F.R. § 42.8.
`
`I.
`
`
`37 C.F.R. § 42.8(b)(1) – Real Party in Interest
`
`The real-party-in-interest is Breckenridge Pharmaceutical, Inc. Breckenridge
`
`identifies the following additional entities as real parties in interest: Pensa Pharma S.A.,
`
`Corporacion Quimico Farmaceutica Esteve, S.A. and Natco Pharma Limited.
`
`II.
`
`
`37 C.F.R. § 42.8(b)(2) – Related Matters
`
`Novartis Pharmaceuticals Corporation and Novartis AG v. West-Ward
`
`Pharmaceuticals International Ltd., C.A. No. 15-0474-RGA (D. Del.); Novartis
`
`Pharmaceuticals Corporation and Novartis AG v. Breckenridge Pharmaceutical, Inc.,
`
`C.A. No. 16-0431-RGA (D. Del.); Novartis Pharmaceuticals Corporation and Novartis
`
`AG v. Teva Pharmaceuticals USA, Inc., C.A. No. 17-0393-RGA (D. Del.); Novartis
`
`Pharmaceuticals Corporation and Novartis AG v. Breckenridge Pharmaceutical, Inc.,
`
`C.A. No. 17-0420-RGA (D. Del.); and Novartis Pharmaceuticals Corporation and
`
`Novartis AG v. Breckenridge Pharmaceutical, Inc., C.A. No. 17-00420-RGA (D. Del.)
`
`which was consolidated with C.A. No. 16-0431-RGA (D. Del.) listed above. According
`
`to USPTO records, U.S. Patent Application No. 15/195,018 claims priority to the ’131
`
`patent and is pending before the USPTO.
`
`III. 37 C.F.R. § 42.8(b)(3) – Lead and Back-Up Counsel
`
`Pursuant to 37 C.F.R. §§ 42.8(b)(3), 42.8(b)(4), and 42.10(a), Breckenridge
`
`provides the following designation of Lead and Back-Up counsel:
`
`1
`
`
`
`LEAD COUNSEL
`Daniel R. Evans
`Registration No. 55,868
`MERCHANT & GOULD P.C.
`191 Peachtree Street, NE
`Suite 3800
`Atlanta, GA 30303
`Main Telephone: 404.954.5100
`Main Facsimile: 612.332.9081
`devans@merchantgould.com
`
`
`Case No. IPR2017-01592
`U.S. Patent No. 8,410,131
`
`
`BACKUP COUNSEL
`Jeffrey D. Blake
`Registration No. 58,884
`MERCHANT & GOULD P.C.
`191 Peachtree Street, NE
`Suite 3800
`Atlanta, GA 30303
`Main Telephone: 404.954.5100
`Main Facsimile: 612.332.9081
`jblake@merchantgould.com
`
`
`
`
`
`
`BACKUP COUNSEL
`Melissa M. Hayworth
`Registration No. 45,774
`MERCHANT & GOULD P.C.
`1900 Duke Street
`Suite 600
`Alexandria, VA 22314
`Main Telephone: 703.684.2500
`Main Facsimile: 612.332.9081
`mhayworth@merchantgould.com
`
`
`IV. 37 C.F.R. § 42.8(b)(4) – Service Information
`
`Please address all correspondence to the counsel identified above. Petitioner also
`
`consents to electronic service by email sent to all email addresses of the counsel identified
`
`above and additionally sent to the following email address:
`
`
`
`V.
`
`
`
`
`
`
`BreckenridgeIPR@merchantgould.com
`
`Power of Attorney
`
`Under 37 C.F.R. § 42.10(a), filed herewith is Updated Petitioner’s Power of Attorney.
`
`
`
`2
`
`
`
`
`
`
`Date: September 12, 2017
`
`Case No. IPR2017-01592
`U.S. Patent No. 8,410,131
`
`
`Respectfully submitted,
`
`
`
`
`By: /Daniel R. Evans/
`Daniel R. Evans, Registration No. 55,868
`Jeffrey D. Blake, Registration No. 58,884
`MERCHANT & GOULD P.C.
`191 Peachtree Street, NE, Suite 3800
`Atlanta, GA 30303
`Main Telephone: 404.954.5100
`Main Facsimile: 612.332.9081
`
`Melissa M. Hayworth
`Registration No. 45,774
`MERCHANT & GOULD P.C.
`1900 Duke Street Suite 600
`Alexandria, VA 22314
`Main Telephone: 703.684.2500
`Main Facsimile: 612.332.9081
`
`Counsel for Petitioner Breckenridge
`Pharmaceutical, Inc.
`
`
`3
`
`
`
`CERTIFICATE OF SERVICE
`
`Case No. IPR2017-01592
`U.S. Patent No. 8,410,131
`
`
`The undersigned hereby certifies that the foregoing Petitioner’s Revised
`
`
`
`Mandatory Disclosures was served in its entirety on September 12, 2017, upon the
`
`following parties via email:
`
`Nicholas N. Kallas
`Fitzpatrick, Cella, Harper & Scinto
`1290 Avenue of the Americas
`New York, NY 10104-2100
`ZortressAfinitorIPR@fchs.com
`
`
`Dated: September 12, 2017
`
`
`
`
`
`Respectfully submitted,
`
`
`
`
`By: /Daniel R. Evans/
`Daniel R. Evans, Registration No. 55,868
`MERCHANT & GOULD P.C.
`191 Peachtree Street, NE, Suite 3800
`Atlanta, GA 30303
`Main Telephone: 404.954.5100
`Main Facsimile: 612.332.9081
`
`Counsel for Petitioner Breckenridge
`Pharmaceutical, Inc.
`
`
`
`
`4
`
`